Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer

Abstract Purpose Ra-223 dichloride (223Ra, Xofigo®) is used for treatment of patients suffering from castration-resistant metastatic prostate cancer. The objective of this work was to apply the most recent biokinetic model for radium and its progeny to show their radiopharmacokinetic behaviour. Orga...

Full description

Bibliographic Details
Main Authors: Vera Höllriegl, Nina Petoussi-Henss, Kerstin Hürkamp, Juan Camilo Ocampo Ramos, Wei Bo Li
Format: Article
Language:English
Published: SpringerOpen 2021-06-01
Series:EJNMMI Physics
Subjects:
Radiopharmaceutical
Biokinetic models
223Ra
Internal dose
Radionuclide therapy
Online Access:https://doi.org/10.1186/s40658-021-00388-1

Internet

https://doi.org/10.1186/s40658-021-00388-1

Similar Items